The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for the treatment of...
Several new studies show how exercise can extend cancer patients’ survival, reduce the risk of recurrence, and improve quality of life.
Researchers explore the causes of lung cancer in never-smokers, and findings support start to colonoscopy screening at age 45.
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with resectable...
The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved mitomycin intravesical solution (Zusduri) for the treatment of adult...
The FDA has approved taletrectinib for certain patients with ROS1-mutated lung cancer. The U.S. Food and Drug Administration (FDA) has approved taletrectinib (Ibtrozi) for the treatment of adult patients with locally advanced or metastatic...
A blood test can detect breast cancer drug resistance, and a combination treatment improves outcomes in colorectal cancer.
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Darolutamide is...
AI can help doctors determine which breast cancer patients qualify for targeted therapy, and cancer deaths among women have increased with rising temperatures in some countries.
This month, the editors of AACR’s journals picked studies highlighting genetic parallels between cancer evolution and high-altitude physiology, data linking oil and gas exposure to childhood leukemia risk, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More